


MRSA in the European Region (EARS-Net and CAESAR), 2017

- <1%
- 1% to <5%
- 5% to <10%
- 10% to <25%
- 25% to <50%
- ≥50%
- No data or <10 isolates
- Not included
- Level B data

- Luxembourg
- Malta



Level B data: the data provide an indication of the resistance patterns present in clinical settings in the country or area, but the proportion of resistance should be interpreted with care. Improvements are needed to attain a more valid assessment of the magnitude and trends of AMR in the country or area. See section 4.2 for more information about levels of evidence, which are only provided for CAESAR countries and areas.

EARS-Net countries: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom.

CAESAR countries and areas: Albania, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Kazakhstan, Kyrgyzstan, Montenegro, the Republic of Moldova, the Russian Federation, Serbia, Switzerland, Tajikistan, the former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Ukraine, Uzbekistan and Kosovo (in accordance with United Nations Security Council resolution 1244 (1999)).

Data sources: 2017 data from the Central Asian and Eastern European Surveillance of Antimicrobial Resistance (CAESAR, ©WHO 2018) and 2017 data from the European Antimicrobial Resistance Surveillance Network (EARS-Net, ©ECDC 2018).